
NAPOLI 3, POUT, & Ivosidenib - Azole DDIs
OncoPharm
00:00
Clinical recommendations for managing the DDI
John recommends monitoring azole levels, considering dose adjustments, and notes no QT concerns observed in the study.
Play episode from 13:45
Transcript


